As I've chronicled in this column year after year, weight-loss and related goals like exercising more and eating better are among the top New Year's resolutions
Schepers E, Barreto DV, Liabeuf S, Glorieux G, Eloot S, et al
FDA approval of exenatide, its first generic injectable GLP-1 agonist, Amneal (2024) Teva announces FDA approval and launch of generic Saxenda (liraglutide injection) first generic GLP-1 indicated for weight loss, Teva Pharmaceuticals (2025) Exenatide, DailyMed (2025) Byetta, DailyMed (2025) Liraglutide (generic Victoza), DailyMed (2025) Liraglutide (generic Saxenda), DailyMed (2025) Victoza, DailyMed (2025) Saxenda, DailyMed (2025) Compounding and the FDA: Questions and answers, U.S
That said, always check with a doctor before starting any new supplement
Based on product descriptions and similar formulations, the capsules probably include stimulants for energy and focus, appetite suppressants, ingredients targeting inflammation, and compounds with some evidence for influencing incretin hormones
VLEKT is characterized by a very low total energy intake (650800 kcal per day), carbohydrate restriction to less than 30 g/day, fat intake of around 20 g/day with a preference for sources of unsaturated fats such as extra-virgin olive oil, and protein intake of 0.81.2 g/kg of reference body weight (i.e., calculated based on the patient's height) ( MAD was developed in 2003 as an alternative to the conventional KD, particularly in the context of treating drug-resistant epilepsy ( MCTKD was developed in 1971 by Huttenlocher et al